About Us
Our Science
Corporate Governance
Investors
Media
Contact

About Us
Our Science
Corporate Governance
Investors
Media
Contact

Contact

You are always welcome to contact us:

Oasmia Pharmaceutical AB
Vallongatan 1
752 28 Uppsala

Telephone: +46 018-50 54 40
Fax: +46 018-51 08 73
E-mail: info@oasmia.com

Q2 report 2020/2021

Oasmia Pharmaceutical will publish its interim report for the second quarter of 2020 on December 9, 2020, at 08.00 am CET.

English Press release - Invitation to presentation of Oasmia’s Q2 report on December 9
Webcast

Read the invitation

The Share

Follow the share

Contact

About Us
Our Science
Corporate Governance
Investors
Media
Contact

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR-17.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Oasmia Pharmaceutical AB
Vallongatan 1, 752 28
Uppsala, Sweden

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com